Seagen/Pfizer's MOUNTAINEER-03 trial for HER2+ colorectal cancer remains active, not recruitingNov 16Trial updatebevacizumabPfizer
The company: FDA grants accelerated approval to tucatinib with trastuzumab for colorectal cancerNov 12Regulatory decisionpertuzumab-dpzbpertuzumab, trastuzumab, and hyaluronidase-zzxfRecord notice
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
FDA approves tucatinib combo for HER2-positive breast cancer maintenanceOct 7Regulatory decisionPfizertucatinib
Pfizer's Ruxience biosimilar supplement approved; breast cancer trials post resultsSep 30Weekly roundup, 8 itemsatirmociclibberobenatideUpdated
FDA approves ZAVZPRET label update; Pfizer registers RSVpreF and prostate cancer studiesAug 21Weekly roundup, 7 itemsBioNTech SEPenbraya
BridgeBio Oncology reports Q2 2026 results, starts two KRAS inhibitor combination trialsAug 11Quarterly updateBridgeBio Oncology Therapeutics, Inc.